"Nichi-Iko", a major generic drug company that is trying to rebuild its management while continuing its business, announced that it is expected to fall into insolvency with liabilities exceeding assets in the interim financial results of the entire group this year.
According to the announcement of "Nichi-Iko", which is headquartered in Toyama City, it is expected that liabilities will exceed assets in the settlement of accounts for the entire group from April to September, which is scheduled to be disclosed on the 14th of this month. increase.
This is because the US subsidiary "Segent Group", which manufactures generic drugs such as injections, experienced an operating loss and product development delays, so the asset value of this subsidiary was reviewed.
This is the first time that Nichi-Iko has become insolvent, and the specific amount will be announced on the 14th of this month.
In March last year, "Nichi-Iko" received a business suspension order from Toyama Prefecture for serious quality control problems, such as shipping pharmaceuticals manufactured in a process not approved by the government, and voluntarily recalled the product.
As a result of this, the final profit and loss for the entire group for the last year was a record deficit of 104.8 billion yen. I am trying to rebuild.
Nichi-Iko commented, "We believe that this situation will not affect business turnaround ADR."